sphingotec GmbH develops diagnostic biomarkers for prediction, and early intervention strategies for acute diseases such as sepsis and acute kidney injury (AKI). The company was established in 2002 by Dr. Andreas Bergmann, one of the founders and managers of B.R.A.H.M.S. AG. As Chief Research Officer he developed the standard-of-care sepsis biomarker Procalcitonin (B.R.A.H.M.S PCT®). sphingotec is located in Hennigsdorf near Berlin, Germany.